Leo Pharma and Almirall signed an agreement to develop a method of sampling skin painless and minimally invasive, that allows for biomarker analysis more accurate and complete clinical trials. The purpose is to advance the dermatological research and knowledge of disease.
It is the first time that two companies come together for the progress of the investigation. Eduardo Sanchíz, CEO of Almirall, commented that “this collaboration will provide the scientific community new tools to understand and treat skin diseases.” While the CEO of Leo Pharma, Gitte Aabo, said that they “feel very proud to join forces with Almirall to the urgent need to have a method of extracting skin samples to be painless , ” he adds. This research project will be conducted at the Clinical Hospital of Barcelona, Technical University of Denmark and the University of Bath.